What changed in this filing

/stocks — the workspaceLOADING

Item 3. Legal Proceedings

2023-02-16 compared with 2022-02-17 · 30 added, 39 removed, 75 unchanged (48% of the section changed)

12 unchanged sentences

Executive Vice President, Global Corporate Affairs (a)

Joaquin Duato 59 Chief Executive Officer;

Chairman, Executive Committee (b)

Joaquin Duato 60 Chairman of the Board;

Chief Executive Officer (b)

Fasolo, Ph.D.

1 unchanged sentence

Executive Vice President, Chief Human Resources Officer (c)

Elizabeth Forminard 52 Member, Executive Committee;

Executive Vice President, General Counsel (d)

Hait, M.D., Ph.

73 Member, Executive Committee;

Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer (d)

Mathai Mammen, Ph.

54 Member, Executive Committee;

Executive Vice President, Pharmaceuticals, R&D (e)

Executive Vice President, Chief External Innovation and Medical Safety Officer;

Interim Head Janssen R&D (e)

Ashley McEvoy 52 Member, Executive Committee;

Executive Vice President, Worldwide Chairman, Medical Devices (f)

Executive Vice President, Worldwide Chairman, MedTech (f)

Thibaut Mongon 53 Member, Executive Committee, Executive Vice President, Worldwide Chairman, Consumer Health (g)

3 unchanged sentences

Executive Vice President, Worldwide Chairman, Pharmaceuticals (i)

Ullmann 63 Member, Executive Committee;

Executive Vice President, General Counsel (j)

Wengel 57 Member, Executive Committee;

Executive Vice President, Chief Global Supply Chain Officer (k)

Executive Vice President, Chief Technical Operations & Risk Officer (j)

Wolk 56 Member, Executive Committee;

Executive Vice President, Chief Financial Officer (l)

Executive Vice President, Chief Financial Officer (k)

Broadhurst joined the Company in 2005 as Worldwide Vice President, Anemia & Oncology Supportive Care.

6 unchanged sentences

In 2018, she was appointed Company Group Chairman, Global Commercial Strategy Organization.

Broadhurst was named Executive Vice President, Global Corporate Affairs and a

member of the Executive Committee, leading the Company's global marketing, communication, design and philanthropy functions.

Duato became Chief Executive Officer and Chairman of the Executive Committee and joined the Board of Directors in January 2022.

Broadhurst was named Executive Vice President, Global Corporate Affairs and a member of the Executive Committee, leading the Company's global marketing, communication, Global Public Health and philanthropy functions.

Duato became Chairman of the Board of Directors in January 2023 subsequent to his appointment as Chief Executive Officer and a Director in January 2022.

He joined the Company in 1989 with Janssen-Farmaceutica S.A.

6 unchanged sentences

Duato's international perspective and global lens gives him a deep appreciation of diverse thoughts and opinions.

Fasolo joined the Company in 2004 as Worldwide Vice President, Human Resources in the Medical Devices segment, and subsequently served as the Company’s Chief Talent Officer.

Fasolo joined the Company in 2004 as Worldwide Vice President, Human Resources in the MedTech segment, and subsequently served as the Company’s Chief Talent Officer.

He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co.

4 unchanged sentences

He also serves on the Boards of the Human Resources Policy Association, Tufts University and Save the Children and was named a Fellow of the National Academy of Human Resources in 2017.

Elizabeth Forminard joined the Company in 2006 as Vice President, Law, Consumer Healthcare Global Business Unit and continued to serve in roles of increasing responsibility.

In 2012, she was promoted to General Counsel, Medical Devices & Diagnostics and became General Counsel, Consumer Group & Supply Chain in 2013.

She was appointed Worldwide Vice President, Corporate Governance in 2016.

From 2019 to 2022, she served as General Counsel, Pharmaceuticals.

In October 2022, she was named Executive Vice President, General Counsel and became a member of the Executive Committee.

Forminard has worldwide responsibility for the legal and privacy functions, and leads the development and execution of the Company's environment, social and governance strategy.

Hait joined the Company in 2007 as Senior Vice President, Worldwide Head of Oncology Research.

4 unchanged sentences

He also has oversight over Global Public Health and the Office of the Chief Medical Officer.

Mammen joined the Company in 2017 as Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson.

Prior to joining Janssen in June 2017, Dr.

Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/lmmuno-Oncology and Immunology.

Prior to Merck, he led R&D at Theravance, a company he co-founded in the San Francisco Bay Area in 1997 based on his work at Harvard University.

In 2022, he was named as Executive Vice President, Pharmaceuticals R&D, and a member of the Executive Committee.

He is responsible for a team whose mission is to make transformational medicines with unequivocal benefit for patients worldwide, working across a wide range of therapeutic areas and biological pathways in the areas of:

Oncology, Cardiovascular and Metabolic Disease, Retinal Disease, Pulmonary Hypertension, Immunology, Neuroscience and Infectious Disease and Vaccines.

These Therapeutic Areas are fueled by world-class Global Functions in Discovery Sciences and Manufacturing, Regulatory Affairs, Development Operations and Data Science.

As Interim Head of Janssen R&D, Dr.

Hait's mission is to focus the best research and development teams in the world at the intersection of unmet medical need and breakthroughs in science and technology to make medicines with benefit for patients worldwide.

McEvoy joined the Company in 1996 as Assistant Brand Manager of McNeil Consumer Health, a subsidiary of the Company, advancing through positions of increasing responsibilities until she was appointed Company Group Chairman, Vision Care in 2012, followed by Company Group Chairman, Consumer Medical Devices in 2014.

In July 2018, Ms.

McEvoy was promoted to Executive Vice President, Worldwide Chairman, Medical Devices, and became a member of the Executive Committee.

McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster and Johnson & Johnson Vision.

McEvoy was promoted to Executive Vice President, Worldwide Chairman, MedTech, and became a member of the Executive Committee.

McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Johnson & Johnson Vision.

Mongon joined the Company in 2000 as Director of Marketing for the Vision Care group in France and subsequently held positions of increasing responsibility until he transitioned to the Pharmaceutical sector in 2012, as the Global Commercial Strategy Leader for the Neuroscience therapeutic area.

6 unchanged sentences

Director IT and Vice President, Chief Information Officer.

responsible for enhancing Johnson & Johnson’s business impact and shaping its direction through the strategic use of technology.

Swanson, Executive Vice President, Chief Information Officer, joined the Executive Committee effective January 3, 2022.

Swanson is responsible for enhancing Johnson & Johnson’s business impact and shaping its direction through the strategic use of technology.

Swanson, Executive Vice President, Enterprise Chief Information Officer, joined the Executive Committee effective January 3, 2022.

Taubert joined the Company in 2005 as Worldwide Vice President, and she held several executive positions of increasing responsibility in the Pharmaceutical sector.

3 unchanged sentences

Taubert is responsible for the Pharmaceutical sector globally, including shaping the company’s strategy of transformational medical innovation and for successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, cardiovascular disease, infectious diseases, pulmonary hypertension and serious mental illness.

Ullmann joined the Company in 1989 as a corporate attorney in the Law Department.

He was appointed Corporate Secretary in 1998 and served in that role until 2006.

During that time, he also held various management positions in the Law Department.

In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012.

In April 2016, Mr.

Ullmann was named Executive Vice President, General Counsel.

Ullmann has worldwide responsibility for legal, government affairs & policy, global security, aviation, healthcare compliance, global brand protection and privacy.

Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company.

During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions.

Wengel became the first Chief Quality Officer of the Company.

In 2014, she was promoted to Vice President, Johnson & Johnson Supply Chain.

In July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee.

Wengel has enterprise-wide responsibilities for Supply Chain, Quality & Compliance, Procurement, Engineering & Property Services, Environmental Health & Safety and Sustainability.

During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions.

In 2018, she was named Executive Vice President, Chief Global Supply

Chain Officer, and became a member of the Executive Committee.

In January 2023, she was appointed Executive Vice President, Chief Technical Operations & Risk Officer.

Wengel has enterprise-wide responsibilities for key technical operations functions, including Procurement, Engineering & Property Services, Sustainability and cross-sector Supply Chain teams focused on standards, services, strategic programs and data science, and serves as Chair of the Company’s Supply Chain Management Committee.

She also oversees critical risk functions, including Quality & Compliance, Health Care Compliance, Environmental Health & Safety, Global Security and Global Brand Protection.

Wolk joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company, and through the years held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, in Pharmaceuticals, Medical Devices and Supply Chain.

4 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 3. Legal Proceedings